New cancer clinical trial: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole

Published on: February 20, 2018 at 12:00PM
Condition:   Breast Cancer
Interventions:   Drug: Ribociclib;   Drug: Letrozole
Sponsor:   Novartis Pharmaceuticals
Not yet recruiting
http://ift.tt/2GyruGv